Percentage of patients aged 18 and older with a diagnosis of heel pain who receive an intervention intended to treat the heel pain and experience a clinically significant decrease in heel pain.
Patients who have had at least two visits during the reporting period
Submission Method: Registry
Use of Structured Reporting for Urine Cytology Specimens
The percentage of Final Reports on Urine cytology specimens, for patients of any age, that utilize The Paris System (TPS) for reporting urinary cytology.
Screening Abdominal Aortic Aneurysm Reporting with Recommendations
Percentage of patients, aged 50-years-old or older, who have had a screening ultrasound for an abdominal aortic aneurysm (AAA), with positive or negative findings, that have recognized clinical follow-up recommendations documented in the final report and direct communication of findings greater than or equal to 5.5 cm in size made to the ordering provider.
Appropriate Classification and Follow-up Imaging for Incidental Pancreatic Cysts
Percentage of final reports for computed tomography/computed tomography angiography (CT/CTA) of the abdomen or abdomen/pelvis or magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) of the abdomen for patients 18 years of age and older with a pancreatic cyst incidentally noted that include documentation of cyst classification/morphology and follow-up imaging recommendation(s) in accordance with published guidelines and source of recommendation.
Reporting Breast Arterial Calcification (BAC) on Screening Mammography
Percentage of Final Screening Mammography Reports for female patients aged 40 years or older that include documentation of the presence or absence of Breast Arterial Calcification (BAC) and its clinical relevance.
Use of Appropriate Classification System for Lymphoma Specimen
Percentage of Final Lymphoma Specimen Pathology Reports, regardless of patient age, that classify the lymphoma using a validated and published model for lymphoma classification**.
** Must be one of the models listed in the Numerator Instructions below.
Appropriate Use of Bethesda System for Reporting Thyroid Cytopathology on Fine Needle Aspirations (FNA) of Thyroid Nodule(s)
Percentage of final pathology reports for thyroid nodule fine needle aspiration (FNA) specimens that include documentation of the diagnostic category, range of estimated risk of malignancy (ROM), and clinical management options in accordance with the Bethesda System for Reporting Cytopathology, 3rd edition (2023), and for thyroid nodule specimens of indeterminate cytology (Bethesda 3 or 4), documentation that direct communication was sent to patient and/or treating physician (if known) to inform them that molecular panel testing may be appropriate.
Intracerebral Hemorrhage (ICH) on Non-Contrast CT Head
All patients 18 years of age and older undergoing non-contrast CT (NCCT) Head with an initial diagnosis of intracerebral hemorrhage (ICH), also referred to as intra-axial or
intraparenchymal hemorrhage (IPH), who have documentation of the location of ICH, ICH volume, and presence or absence of intraventricular hemorrhage (IVH) in the Final Report.
Immunohistochemistry (IHC) and/or Molecular BRAF Testing Status in Metastatic Melanoma
Percentage of final immunohistochemical staining reports for patients with an initial diagnosis of metastatic melanoma that contain a recommendation for or the results of BRAF testing (either by immunohistochemistry (IHC) and/or molecular testing).
Use of Appropriate Scoring System for Immunohistochemistry (IHC) for HER2/neu Testing for Invasive Breast Cancer
Percentage of final pathology reports for immunohistochemistry (IHC) for HER2/neu testing for invasive breast cancer that include interpretation of the results in accordance with the 2018, 2023 or later ASCO-CAP Guideline Update.